Current challenges and practical aspects of molecular pathology for non-small cell lung cancers
Authors:
Open Access
- 6 October 2023
- journal article
- review article
- Published by Springer Nature in Virchows Archiv
- Vol. 484 (2) , 233-246
Abstract
The continuing evolution of treatment options in thoracic oncology requires the pathologist to regularly update diagnostic algorithms for management of tumor samples. It is essential to decide on the best way to use tissue biopsies, cytological samples, as well as liquid biopsies to identify the different mandatory predictive biomarkers of lung cancers in a short turnaround time. However, biological resources and laboratory member workforce are limited and may be not sufficient for the increased complexity of molecular pathological analyses and for complementary translational research development. In this context, the surgical pathologist is the only one who makes the decisions whether or not to send specimens to immunohistochemical and molecular pathology platforms. Moreover, the pathologist can rapidly contact the oncologist to obtain a new tissue biopsy and/or a liquid biopsy if he/she considers that the biological material is not sufficient in quantity or quality for assessment of predictive biomarkers. Inadequate control of algorithms and sampling workflow may lead to false negative, inconclusive, and incomplete findings, resulting in inappropriate choice of therapeutic strategy and potentially poor outcome for patients. International guidelines for lung cancer treatment are based on the results of the expression of different proteins and on genomic alterations. These guidelines have been established taking into consideration the best practices to be set up in clinical and molecular pathology laboratories. This review addresses the current predictive biomarkers and algorithms for use in thoracic oncology molecular pathology as well as the central role of the pathologist, notably in the molecular tumor board and her/his participation in the treatment decision-making. The perspectives in this setting will be discussed.Keywords
This publication has 112 references indexed in Scilit:
- Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?Translational Lung Cancer Research, 2018
- Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?Cancers, 2018
- Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2018
- Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?Cancers, 2018
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular PathologyArchives of Pathology & Laboratory Medicine, 2018
- Lung Cancer BiomarkersHematology/Oncology Clinics of North America, 2017
- Sense and nonsense in the process of accreditation of a pathology laboratoryVirchows Archiv, 2015
- The Pre-analytical Phase in Surgical Pathology2015
- Current concepts on the molecular pathology of non-small cell lung carcinomaSeminars in Diagnostic Pathology, 2014
- Pitfalls in Lung Cancer Molecular Pathology: How to Limit them in Routine Practice?Current Medicinal Chemistry, 2012